NextCure, Inc. Common Stock (NXTC)
NextCure, Inc. is a biopharmaceutical company focused on developing immuno-oncology therapies to treat cancer. Founded to leverage groundbreaking research in immunology, the company aims to discover and develop novel monoclonal antibodies that can modulate immune responses and improve outcomes for cancer patients.
Company News
NextCure reported a Q2 2025 net loss of $26.8 million, primarily due to a $17.0 million license fee for SIM0505. The company advanced its lead clinical programs LNCB74 and SIM0505, with proof-of-concept data expected in the first half of 2026.
NextCure, a clinical-stage biopharmaceutical company, announced the completion of cohort 1 of the Phase 1 trial for its B7-H4 ADC drug candidate and plans to initiate backfill cohorts in the second half of 2025. The company reported a cash position of approximately $68.6 million.
Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. See why PYXS stock is a Hold.
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates. Amtech reported quarterly sales of $27.70 million, missing the analyst consensus estimate of $34.50 million. The company...